{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:31:20Z","timestamp":1788618680914,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess patient\u2010reported outcomes (PROs) in the SoliMix trial, which compared the efficacy and safety of iGlarLixi versus BIAsp 30 in people with type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>SoliMix (EudraCT: 2017\u2010003370\u201013), a 26\u2010week, open\u2010label study, randomized (1:1) 887 adults with T2D and HbA1c\u00a0\u22657.5%\u2010\u226410.0% (\u226558\u2010\u226486 mmol\/mol) on basal insulin plus oral antihyperglycaemic drugs (OADs) to once\u2010daily iGlarLixi or twice\u2010daily premix insulin, BIAsp 30. PROs were assessed using the Treatment\u2010Related Impact Measure Diabetes (TRIM\u2010D) and Global Treatment Effectiveness Evaluation (GTEE) questionnaires.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over 26\u2009weeks, iGlarLixi showed greater improvement from baseline versus BIAsp 30 in total TRIM\u2010D score (least squares mean difference [95% confidence interval]: 5.08 [3.69, 6.47]; effect size: 0.32) and in each TRIM\u2010D domain, with the greatest differences seen in diabetes management (8.47 [6.11, 10.84]) and treatment burden (6.95 [4.83, 9.07]). GTEE scores showed a greater proportion of participants and physicians rated a complete or marked improvement of diabetes control with iGlarLixi (80.5%, 82.8%) versus BIAsp 30 (63.3%, 65.1%) at week 26. Post hoc analyses showed that after adjusting for HbA1c, body weight and hypoglycaemia outcomes, iGlarLixi continued to show greater improvements in TRIM\u2010D total scores versus BIAsp 30.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In addition to better glycaemic control, weight benefit and less hypoglycaemia, once\u2010daily iGlarLixi provided improved diabetes management, treatment burden and perceived effectiveness versus twice\u2010daily premix BIAsp 30, further supporting iGlarLixi as an advanced treatment option in people with suboptimally controlled T2D on basal insulin plus OADs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14822","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T04:49:59Z","timestamp":1661230199000},"page":"2364-2372","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Improved patient\u2010reported outcomes with\n                    <scp>iGlarLixi<\/scp>\n                    versus premix\n                    <scp>BIAsp<\/scp>\n                    30 in people with type 2 diabetes in the\n                    <scp>SoliMix<\/scp>\n                    trial"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9064-6144","authenticated-orcid":false,"given":"William H.","family":"Polonsky","sequence":"first","affiliation":[{"name":"Behavioral Diabetes Institute  San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-2678","authenticated-orcid":false,"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases University of Bari Aldo Moro  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes Research Center at Medical City  Dallas Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Whitmire","sequence":"additional","affiliation":[{"name":"Southwest Medical Associates  Las Vegas Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5097-0169","authenticated-orcid":false,"given":"Elisheva","family":"Lew","sequence":"additional","affiliation":[{"name":"Sanofi  Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Coudert","sequence":"additional","affiliation":[{"name":"Biostatistics and Programming Department Sanofi  Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Sanofi  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4856-4369","authenticated-orcid":false,"given":"Charlie","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Sanofi  Reading UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-1981","authenticated-orcid":false,"given":"Rory J.","family":"McCrimmon","sequence":"additional","affiliation":[{"name":"Division of Systems Medicine, School of Medicine University of Dundee  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4729-5"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S009"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106821"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13132"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03605.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0395-3"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.06.003"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1348"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0117.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0393"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1357"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14354"},{"key":"e_1_2_9_16_1","unstructured":"Sanofi. Suliqua: Summary of product characteristics2022.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/suliqua. Accessed March 2022."},{"key":"e_1_2_9_17_1","unstructured":"Novo Nordisk. NovoMix: Summary of product characteristics2020.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/novomix-epar-product-information_en.pdf. Accessed January 2022."},{"key":"e_1_2_9_18_1","unstructured":"Novo Nordisk.NovoMix: Prescribing information 2012.https:\/\/media.mycme.com\/documents\/42\/novomix_30_pi_march_2012_10453.pdf. Accessed January2022."},{"key":"e_1_2_9_19_1","unstructured":"Sanofi.Soliqua: Prescribing information 2021.https:\/\/products.sanofi.us\/soliqua100-33\/soliqua100-33.pdf. Accessed March2022."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-83"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9886-7"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02522.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsp004"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.29.3.166"},{"key":"e_1_2_9_25_1","volume-title":"Treatment Persistence and Adherence in People with Type 2 Diabetes Switching to iGlarLixi Vs Free\u2010Dose Combinations of Basal Insulin and Glucagon\u2010like Peptide 1 Receptor Agonist","author":"Edelman SCD","year":"2021"},{"key":"e_1_2_9_26_1","volume-title":"iGlarLixi vs Premixed Insulin Initiation in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: SoliComplex Real\u2010World Study","author":"Lajara R","year":"2022"},{"key":"e_1_2_9_27_1","volume-title":"Initiation of iGlarLixi vs. Basal\u2010Bolus Insulin (BB) in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: The SoliComplex Real\u2010World Study","author":"Pantalone KM","year":"2022"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14822","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14822","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:30:36Z","timestamp":1761885036000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/dom.14822"],"URL":"https:\/\/doi.org\/10.1111\/dom.14822","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"2022-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}